Early lymphocyte collection for <scp>anti‐CD19 CART</scp> production improves T‐cell fitness in patients with relapsed/refractory diffuse large B‐cell lymphoma

Abstract

While improved T-cell phenotype and function in the lymphopheresis product did not translate into significantly improved clinical outcomes, a trend towards better overall survival (OS) and progression-free survival (PFS) was observed. Early lymphopheresis maximizes the potential of salvage therapies, without compromising CAR T-cell quality.